The immunology of influenza virus-associated bacterial pneumonia

Current Opinion in Immunology

Volumn 34, Issue , 2015, Pages 59-67

  Robinson, Keven M ^a   Kolls, Jay K ^b   Alcorn, John F ^b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; POLYPEPTIDE ANTIBIOTIC AGENT;

ADAPTIVE IMMUNITY; BACTERIAL PNEUMONIA; DISEASE ASSOCIATION; DISEASE SEVERITY; DNA MODIFICATION; HUMAN; IMMUNOMODULATION; INFECTION SENSITIVITY; INFLUENZA; INFLUENZA VIRUS; INNATE IMMUNITY; LYMPHOCYTE; MORBIDITY; MORTALITY; NONHUMAN; PHAGOCYTE; REVIEW; SECONDARY INFECTION; SUPERINFECTION; ANIMAL; COMPLICATION; GENETICS; IMMUNOLOGY; MICROBIOLOGY; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRUS INFECTION; PHYSIOLOGY; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

ANIMALS; HUMANS; INFLUENZA, HUMAN; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; PHAGOCYTES; PNEUMONIA, BACTERIAL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

EID: 84923300808     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2015.02.002     Document Type: Review

References (57)

1. Morens D.M., Taubenberger J.K., Fauci A.S. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis 2008, 198:962-970.
2. Rice T.W., Rubinson L., Uyeki T.M., Vaughn F.L., John B.B., Miller R.R., Higgs E., Randolph A.G., Smoot B.E., Thompson B.T. Critical illness from 2009 pandemic influenza A virus and bacterial coinfection in the United States. Crit Care Med 2012, 40:1487-1498.
3. Shannon S. Surveillance for pediatric deaths associated with 2009 pandemic influenza A (H1N1) virus infection - United States, April-August 2009. CDC MMWR Wkly 2009, 58:941-947.
4. Shieh W.J., Blau D.M., Denison A.M., Deleon-Carnes M., Adem P., Bhatnagar J., Sumner J., Liu L., Patel M., Batten B., et al. 2009 pandemic influenza A (H1N1): pathology and pathogenesis of 100 fatal cases in the United States. Am J Pathol 2010, 177:166-175.
5. Blyth C.C., Webb S.A., Kok J., Dwyer D.E., van Hal S.J., Foo H., Ginn A.N., Kesson A.M., Seppelt I., Iredell J.R. The impact of bacterial and viral co-infection in severe influenza. Influenza Other Respir Virus 2013, 7:168-176.
6. Randolph A.G., Vaughn F., Sullivan R., Rubinson L., Thompson B.T., Yoon G., Smoot E., Rice T.W., Loftis L.L., Helfaer M., et al. Critically ill children during the 2009-2010 influenza pandemic in the United States. Pediatrics 2011, 128:e1450-e1458.
7. Gill J.R., Sheng Z.M., Ely S.F., Guinee D.G., Beasley M.B., Suh J., Deshpande C., Mollura D.J., Morens D.M., Bray M., et al. Pulmonary pathologic findings of fatal 2009 pandemic influenza A/H1N1 viral infections. Arch Pathol Lab Med 2010, 134:235-243.
8. Palacios G., Hornig M., Cisterna D., Savji N., Bussetti A.V., Kapoor V., Hui J., Tokarz R., Briese T., Baumeister E., et al. Streptococcus pneumoniae coinfection is correlated with the severity of H1N1 pandemic influenza. PLoS ONE 2009, 4:e8540.
9. Nguyen T., Kyle U.G., Jaimon N., Tcharmtchi M.H., Coss-Bu J.A., Lam F., Teruya J., Loftis L. Coinfection with Staphylococcus aureus increases risk of severe coagulopathy in critically ill children with influenza A (H1N1) virus infection. Crit Care Med 2012, 40:3246-3250.
10. Ampofo K., Herbener A., Blaschke A.J., Heyrend C., Poritz M., Korgenski K., Rolfs R., Jain S., Carvalho M.da.G., Pimenta F.C., et al. Association of 2009 pandemic influenza A (H1N1) infection and increased hospitalization with parapneumonic empyema in children in Utah. Pediatr Infect Dis J 2010, 29:905-909.
11. Ghoneim H.E., Thomas P.G., McCullers J.A. Depletion of alveolar macrophages during influenza infection facilitates bacterial superinfections. J Immunol 2013, 191:1250-1259.
12. Kudva A., Scheller E.V., Robinson K.M., Crowe C.R., Choi S.M., Slight S.R., Khader S.A., Dubin P.J., Enelow R.I., Kolls J.K., et al. Influenza A inhibits Th17-mediated host defense against bacterial pneumonia in mice. J Immunol 2011, 186:1666-1674.
13. Damjanovic D., Lai R., Jeyanathan M., Hogaboam C.M., Xing Z. Marked improvement of severe lung immunopathology by influenza-associated pneumococcal superinfection requires the control of both bacterial replication and host immune responses. Am J Pathol 2013, 183:868-880.
14. Mediavilla J.R., Chen L., Mathema B., Kreiswirth B.N. Global epidemiology of community-associated methicillin resistant Staphylococcus aureus (CA-MRSA). Curr Opin Microbiol 2012, 15:588-595.
15. Niemann S., Ehrhardt C., Medina E., Warnking K., Tuchscherr L., Heitmann V., Ludwig S., Peters G., Loffler B. Combined action of influenza virus and Staphylococcus aureus panton-valentine leukocidin provokes severe lung epithelium damage. J Infect Dis 2012, 206:1138-1148.
16. Didierlaurent A., Goulding J., Patel S., Snelgrove R., Low L., Bebien M., Lawrence T., van Rijt L.S., Lambrecht B.N., Sirard J.C., et al. Sustained desensitization to bacterial Toll-like receptor ligands after resolution of respiratory influenza infection. J Exp Med 2008, 205:323-329.
17. Robinson K.M., McHugh K.J., Mandalapu S., Clay M.E., Lee B., Scheller E.V., Enelow R.I., Chan Y.R., Kolls J.K., Alcorn J.F. Influenza A virus exacerbates Staphylococcus aureus pneumonia in mice by attenuating antimicrobial peptide production. J Infect Dis 2014, 209:865-875.
18. Sun K., Metzger D.W. Influenza infection suppresses NADPH oxidase-dependent phagocytic bacterial clearance and enhances susceptibility to secondary methicillin-resistant Staphylococcus aureus infection. J Immunol 2014, 192:3301-3307.
19. Subramaniam R., Barnes P.F., Fletcher K., Boggaram V., Hillberry Z., Neuenschwander P., Shams H. Protecting against post-influenza bacterial pneumonia by increasing phagocyte recruitment and ROS production. J Infect Dis 2014, 209:1827-1836.
20. Brinkmann V., Reichard U., Goosmann C., Fauler B., Uhlemann Y., Weiss D.S., Weinrauch Y., Zychlinsky A. Neutrophil extracellular traps kill bacteria. Science 2004, 303:1532-1535.
21. Fuchs T.A., Abed U., Goosmann C., Hurwitz R., Schulze I., Wahn V., Weinrauch Y., Brinkmann V., Zychlinsky A. Novel cell death program leads to neutrophil extracellular traps. J Cell Biol 2007, 176:231-241.
22. Narasaraju T., Yang E., Samy R.P., Ng H.H., Poh W.P., Liew A.A., Phoon M.C., van Rooijen N., Chow V.T. Excessive neutrophils and neutrophil extracellular traps contribute to acute lung injury of influenza pneumonitis. Am J Pathol 2011, 179:199-210.
23. Narayana Moorthy A., Narasaraju T., Rai P., Perumalsamy R., Tan K.B., Wang S., Engelward B., Chow V.T. In vivo and in vitro studies on the roles of neutrophil extracellular traps during secondary pneumococcal pneumonia after primary pulmonary influenza infection. Front Immunol 2013, 4:56.
24. Xu J., Zhang X., Pelayo R., Monestier M., Ammollo C.T., Semeraro F., Taylor F.B., Esmon N.L., Lupu F., Esmon C.T. Extracellular histones are major mediators of death in sepsis. Nat Med 2009, 15:1318-1321.
25. Shahangian A., Chow E.K., Tian X., Kang J.R., Ghaffari A., Liu S.Y., Belperio J.A., Cheng G., Deng J.C. Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice. J Clin Investig 2009, 119:1910-1920.
26. Schliehe C., Flynn E.K., Vilagos B., Richson U., Swaminathan S., Bosnjak B., Bauer L., Kandasamy R.K., Griesshammer I.M., Kosack L., et al. The methyltransferase Setdb2 mediates virus-induced susceptibility to bacterial superinfection. Nat Immunol 2015, 16:67-74.
27. Li W., Moltedo B., Moran T.M. Type I interferon induction during influenza virus infection increases susceptibility to secondary Streptococcus pneumoniae infection by negative regulation of gammadelta T cells. J Virol 2012, 86:12304-12312.
28. Nakamura S., Davis K.M., Weiser J.N. Synergistic stimulation of type I interferons during influenza virus coinfection promotes Streptococcus pneumoniae colonization in mice. J Clin Investig 2011, 121:3657-3665.
29. Tian X., Xu F., Lung W.Y., Meyerson C., Ghaffari A.A., Cheng G., Deng J.C. Poly I:C enhances susceptibility to secondary pulmonary infections by gram-positive bacteria. PLoS ONE 2012, 7:e41879.
30. Sun K., Metzger D.W. Inhibition of pulmonary antibacterial defense by interferon-gamma during recovery from influenza infection. Nat Med 2008, 14:558-564.
31. Rynda-Apple A., Harmsen A., Erickson A.S., Larson K., Morton R.V., Richert L.E., Harmsen A.G. Regulation of IFN-gamma by IL-13 dictates susceptibility to secondary postinfluenza MRSA pneumonia. Eur J Immunol 2014, 44:3263-3272.
32. Ivanov S., Renneson J., Fontaine J., Barthelemy A., Paget C., Fernandez E.M., Blanc F., De Trez C., Van Maele L., Dumoutier L., et al. Interleukin-22 reduces lung inflammation during influenza A virus infection and protects against secondary bacterial infection. J Virol 2013, 87:6911-6924.
33. Robinson K.M., Choi S.M., McHugh K.J., Mandalapu S., Enelow R.I., Kolls J.K., Alcorn J.F. Influenza A exacerbates Staphylococcus aureus pneumonia by attenuating IL-1beta production in mice. J Immunol 2013, 191:5153-5159.
34. McHugh K.J., Mandalapu S., Kolls J.K., Ross T.M., Alcorn J.F. A novel outbred mouse model of 2009 pandemic influenza and bacterial co-infection severity. PLOS ONE 2013, 8:e82865.
35. Cao J., Wang D., Xu F., Gong Y., Wang H., Song Z., Li D., Zhang H., Zhang L., Xia Y., et al. Activation of IL-27 signalling promotes development of postinfluenza pneumococcal pneumonia. EMBO Mol Med 2014, 6:120-140.
36. Small C.L., Shaler C.R., McCormick S., Jeyanathan M., Damjanovic D., Brown E.G., Arck P., Jordana M., Kaushic C., Ashkar A.A., et al. Influenza infection leads to increased susceptibility to subsequent bacterial superinfection by impairing NK cell responses in the lung. J Immunol 2010, 184:2048-2056.
37. Goulding J., Godlee A., Vekaria S., Hilty M., Snelgrove R., Hussell T. Lowering the threshold of lung innate immune cell activation alters susceptibility to secondary bacterial superinfection. J Infect Dis 2011, 204:1086-1094.
38. McNamee L.A., Harmsen A.G. Both influenza-induced neutrophil dysfunction and neutrophil-independent mechanisms contribute to increased susceptibility to a secondary Streptococcus pneumoniae infection. Infection and immunity 2006, 74:6707-6721.
39. van der Sluijs K.F., van Elden L.J., Nijhuis M., Schuurman R., Pater J.M., Florquin S., Goldman M., Jansen H.M., Lutter R., van der Poll T. IL-10 is an important mediator of the enhanced susceptibility to pneumococcal pneumonia after influenza infection. J Immunol 2004, 172:7603-7609.
40. Bedoya F., Cheng G.S., Leibow A., Zakhary N., Weissler K., Garcia V., Aitken M., Kropf E., Garlick D.S., Wherry E.J., et al. Viral antigen induces differentiation of Foxp3+ natural regulatory T cells in influenza virus-infected mice. J Immunol 2013, 190:6115-6125.
41. van der Sluijs K.F., Nijhuis M., Levels J.H., Florquin S., Mellor A.L., Jansen H.M., van der Poll T., Lutter R. Influenza-induced expression of indoleamine 2,3-dioxygenase enhances interleukin-10 production and bacterial outgrowth during secondary pneumococcal pneumonia. J Infect Dis 2006, 193:214-222.
42. Monticelli L.A., Sonnenberg G.F., Abt M.C., Alenghat T., Ziegler C.G., Doering T.A., Angelosanto J.M., Laidlaw B.J., Yang C.Y., Sathaliyawala T., et al. Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus. Nat Immunol 2011, 12:1045-1054.
43. Blok D.C., van der Sluijs K.F., Florquin S., de Boer O.J., van 't Veer C., de Vos A.F., van der Poll T. Limited anti-inflammatory role for interleukin-1 receptor like 1 (ST2) in the host response to murine postinfluenza pneumococcal pneumonia. PLOS ONE 2013, 8:e58191.
44. Picard C., Casanova J.L., Puel A. Infectious diseases in patients with IRAK-4, MyD88, NEMO, or IkappaBalpha deficiency. Clin Microbiol Rev 2011, 24:490-497.
45. Albiger B., Sandgren A., Katsuragi H., Meyer-Hoffert U., Beiter K., Wartha F., Hornef M., Normark S., Normark B.H. Myeloid differentiation factor 88-dependent signalling controls bacterial growth during colonization and systemic pneumococcal disease in mice. Cell Microbiol 2005, 7:1603-1615.
46. Holland S.M., DeLeo F.R., Elloumi H.Z., Hsu A.P., Uzel G., Brodsky N., Freeman A.F., Demidowich A., Davis J., Turner M.L., et al. STAT3 mutations in the hyper-IgE syndrome. N Engl J Med 2007, 357:1608-1619.
47. Minegishi Y., Saito M., Nagasawa M., Takada H., Hara T., Tsuchiya S., Agematsu K., Yamada M., Kawamura N., Ariga T., et al. Molecular explanation for the contradiction between systemic Th17 defect and localized bacterial infection in hyper-IgE syndrome. J Exp Med 2009, 206:1291-1301.
48. Choi S.M., McAleer J.P., Zheng M., Pociask D.A., Kaplan M.H., Qin S., Reinhart T.A., Kolls J.K. Innate Stat3-mediated induction of the antimicrobial protein Reg3gamma is required for host defense against MRSA pneumonia. J Exp Med 2013, 210:551-561.
49. Seo S.U., Kwon H.J., Song J.H., Byun Y.H., Seong B.L., Kawai T., Akira S., Kweon M.N. MyD88 signaling is indispensable for primary influenza A virus infection but dispensable for secondary infection. J Virol 2010, 84:12713-12722.
50. Wang W.B., Levy D.E., Lee C.K. STAT3 negatively regulates type I IFN-mediated antiviral response. J Immunol 2011, 187:2578-2585.
51. Ghoneim H.E., McCullers J.A. Adjunctive corticosteroid therapy improves lung immunopathology and survival during severe secondary pneumococcal pneumonia in mice. J Infect Dis 2014, 209:1459-1468.
52. Karlstrom A., Heston S.M., Boyd K.L., Tuomanen E.I., McCullers J.A. Toll-like receptor 2 mediates fatal immunopathology in mice during treatment of secondary pneumococcal pneumonia following influenza. J Infect Dis 2011, 204:1358-1366.
53. Breslow-Deckman J.M., Mattingly C.M., Birket S.E., Hoskins S.N., Ho T.N., Garvy B.A., Feola D.J. Linezolid decreases susceptibility to secondary bacterial pneumonia postinfluenza infection in mice through its effects on IFN-gamma. J Immunol 2013, 191:1792-1799.
54. Liu X., He Y., Xiao K., White J.R., Fusco D.N., Papanicolaou G.A. Effect of linezolid on clinical severity and pulmonary cytokines in a murine model of influenza A and Staphylococcus aureus coinfection. PLOS ONE 2013, 8:e57483.
55. Lin K.L., Sweeney S., Kang B.D., Ramsburg E., Gunn M.D. CCR2-antagonist prophylaxis reduces pulmonary immune pathology and markedly improves survival during influenza infection. J Immunol 2011, 186:508-515.
56. Tanaka A., Nakamura S., Seki M., Fukudome K., Iwanaga N., Imamura Y., Miyazaki T., Izumikawa K., Kakeya H., Yanagihara K., et al. Toll-like receptor 4 agonistic antibody promotes innate immunity against severe pneumonia induced by coinfection with influenza virus and Streptococcus pneumoniae. Clin Vaccine Immunol: CVI 2013, 20:977-985.
57. Robinson K.M., Lee B., Scheller E.V., Mandalapu S., Enelow R.I., Kolls J.K., Alcorn J.F. The role of IL-27 in susceptibility to post-influenza Staphylococcus aureus pneumonia. Respir Res 2015, 16:10.